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The filoviruses Ebolavirus (EBOV) and Marburgvirus (MARV) cause severe hemorrhagic fever in humans and are potential agents of
biological warfare. The envelope glycoprotein (GP) of filoviruses mediates viral entry into cells and is an attractive target for therapeutic
intervention and vaccine design. Here, we asked if the efficiency of virion incorporation of EBOV-GP impacts attachment and entry into target
cells and modulates susceptibility to neutralizing antibodies. In order to control the level of EBOV-GP expression, we generated cell lines
expressing the GPs of the four known EBOV subspecies in an inducible fashion. Regulated expression of GP on the cell surface allowed
production of reporter viruses harboring different amounts of GP. A pronounced reduction of virion incorporation of EBOV-GP had relatively little
effect on virion infectivity, suggesting that only a few copies of GP might be sufficient for efficient engagement of cellular receptors. In contrast,
optimal interactions with cellular attachment factors like the DC-SIGN protein required incorporation of high amounts of GP. Antibody-mediated
neutralization of virions bearing high amounts of GP was slightly more efficient than neutralization of virions harboring low amounts of GP,
suggesting that the efficiency of GP incorporation into virions might modulate susceptibility to neutralizing antibodies. Finally, regulated
expression of GP in permissive 293 cells did not reduce EBOV-GP-driven infection but diminished vesicular stomatitis virus GP (VSV-G) and
amphotropic murine leukemia virus (A-MLV) GP mediated entry in a dose-dependent manner. Therefore, intracellular GP does not seem to
downmodulate expression of its receptor(s) but might alter expression and/or function of molecules involved in VSV-G and A-MLV-GP-
dependent entry. Our results suggest that the efficiency of virion incorporation of GP could impact EBOV attachment to target cells and might
modulate control of viral spread by the humoral immune response.
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The filoviruses Ebolavirus (EBOV) and Marburgvirus
(MARV) are negative stranded RNA viruses that cause severe
hemorrhagic fever in humans (Feldmann et al., 2003; Geisbert
and Hensley, 2004). The genus EBOV contains four subspecies,
Zaire ebolavirus (ZEBO), Sudan ebolavirus (SEBOV), Ivory
coast ebolavirus (ICEBOV) and Reston ebolavirus (REBOV),
while Lake Victoria MARV is the only member of the MARV
genus. The EBOV subtypes exhibit differential pathogenicity in
humans. ZEBOV infection is lethal in up to 90% of the cases,⁎ Corresponding author. Nikolaus-Fiebiger-Center for Molecular Medicine,
Glückstraße 6, 91054 Erlangen, Germany. Fax: +49 9131 8529111.
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doi:10.1016/j.virol.2006.04.038while REBOV is considered nonpathogenic (Feldmann et al.,
2003; Geisbert and Hensley, 2004). However, the underlying
pathogenicity determinants are incompletely understood. The
first step of the viral life cycle, entry into target cells, is
mediated by the envelope glycoprotein (GP) (Kawaoka, 2005).
EBOV- and MARV-GP is encoded by the fourth gene of the
viral genome (Sanchez et al., 1993; Volchkov et al., 1992; Will
et al., 1993). The EBOV- but not the MARV-GP gene contains
two open reading frames. The major product synthesized from
the EBOV-GP gene is a secreted form of GP, termed small GP
(sGP) (Sanchez et al., 1996; Volchkov et al., 1995), which is not
produced in MARV infected cells. The role of sGP in EBOV
infection is incompletely defined (Kindzelskii et al., 2000;
Maruyama et al., 98 A.D.; Yang et al., 1998). About 20% of the
EBOV-GP message is transcriptionally edited by the viral
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(Volchkov et al., 1995). The membrane bound EBOV- and
MARV-GP is incorporated into budding virions and mediates
entry into target cells (Kawaoka, 2005).
An N-terminal signal peptide targets the nascent GP into the
endoplasmatic reticulum, where the polypeptide chain is
modified with high mannose carbohydrates (Feldmann et al.,
1991, 1994; Will et al., 1993). Subsequently, posttranslational
modification of GP continues in the Golgi apparatus, and upon
transport into the trans-Golgi, GP is cleaved by the cellular
endoprotease furin into the subunits GP1 and GP2 (Volchkov et
al., 1998). GP1 and GP2 remain covalently associated via
disulfide bonds (Volchkov et al., 1998) and form trimeric
heterodimers in the cellular membrane (Malashkevich et al.,
1999), where they are incorporated into budding virions
(Jasenosky and Kawaoka, 2004). Expression of GP of the
highly pathogenic ZEBOV subspecies downmodulates cellular
surface proteins, triggers detachment of adherent cells in culture
and disrupts the integrity of the vascular endothelium (Chan et
al., 2000; Simmons et al., 2002; Takada et al., 2000; Yang et al.,
2000). Its has therefore been proposed that GP is an important
determinant of viral pathogenicity and might be responsible for
development of hemorrhages (Yang et al., 2000). While the
latter concept has been challenged (Geisbert et al., 2003), the
cytopathic effect of GP is undisputed. In fact, a major purpose
of sGP synthesis might be to limit expression of GP in infected
cells (Volchkov et al., 2001).
The functional organization of EBOV-GP is similar to that of
various other viral glycoproteins, termed class I fusion proteins
(Kawaoka, 2005). Thus, the GP1 subunit is believed to interact
with cellular receptors, while the GP2 subunit, which is oriented
perpendicular to the viral membrane, drives fusion of the viral
and a cellular membrane, thereby allowing delivery of the viral
genome into the cellular cytoplasm (Kawaoka, 2005). The
fusion machinery in GP2 has been defined on a functional and
structural basis (Ito et al., 1999; Malashkevich et al., 1999;
Watanabe et al., 2000; Weissenhorn et al., 1998a, 1998b).
However, the elements in GP1 required for recognition of
cellular receptors are less clear. Recent mutagenic analysis
suggested that the N-terminal 150 amino acids might be
involved in receptor binding (Manicassamy et al., 2005). In
contrast, a C-terminal mucin-like domain, which exhibits high
variability between the EBOV subspecies and constitutes a
determinant of cytopathicity (Simmons et al., 2002; Yang et al.,
2000), is dispensable for GP-driven infection (Yang et al.,
2000). Engagement of cellular receptors by GP1 is believed to
introduce EBOV into endosomal vesicles, where cathepsin
mediated proteolysis of GP1 triggers the membrane fusion
activity of GP2 (Chandran et al., 2005; Kawaoka, 2005;
Schornberg et al., 2006). While the cellular receptor(s) for
filoviruses remain elusive, binding of GP to several cellular
lectins was shown to profoundly augment filovirus infection
(Alvarez et al., 2002; Becker et al., 1995; Gramberg et al., 2005;
Lin et al., 2003; Simmons et al., 2003; Takada et al., 2004).
GP is a target for neutralizing antibodies, and such antibodies
can provide protection against EBOV infection in small animal
models (Wilson et al., 2000). However, the generation ofneutralizing antibodies is inefficient in infected individuals
(Peters and LeDuc, 1999). Nevertheless, GP-specific neutral-
izing antibodies have been detected in convalescent donors
(Maruyama et al., 1999). Because of its indispensable function
in the viral life cycle and its susceptibility to antibody inhibition
GP is a key target for therapeutic intervention and vaccine
development. Thus, immunization with GP encoding adeno-
viruses (Sullivan et al., 2000, 2003) or vesicular stomatitis
viruses (Jones et al., 2005) protected macaques from filovirus
infection, and these vaccines are attractive candidates for
evaluation in humans.
It is appreciated that expression levels of GP in infected cells
impact cellular viability and virus production (Simmons et al.,
2002; Volchkov et al., 2001). However, it is unclear if the
efficiency of GP incorporation into budding virions affects the
interaction with cellular factors and the recognition by the
humoral immune response. For simian immunodeficiency virus
(SIV), it has been reported that the efficiency of envelope
protein (Env) incorporation into virions can profoundly
modulate infectivity and neutralization sensitivity (Yuste et
al., 2004, 2005), and a correlation between Env content in
virions and virion infectivity has also been observed for human
immunodeficiency virus type-1 (HIV-1) (Bachrach et al., 2005).
By employing cell lines that express EBOV-GP of the four
subspecies upon induction, we investigated how the level of
EBOV-GP incorporation into virions affects the interaction with
cellular factors and the susceptibility to antibody neutralization.
We provide evidence that relative few copies of GP are
sufficient to allow robust infection, while only high amounts of
GP allow optimal engagement of cellular lectins. We also show
that the density of GP on virions can impact neutralization
efficiency and that the expression of high levels of GP by target
cells does not interfere with EBOV-GP mediated infection.
Results
Inducible expression of EBOV-GPs by 293 T-REx cells
We sought to investigate if the efficiency of virion
incorporation of EBOV-GP affects the interaction of virions
with cellular factors and their recognition by neutralizing
antibodies. In order to generate virions harboring different copy
numbers of GP, we employed a tetracycline inducible system to
express GP. Thus, expression constructs for the GPs of the four
EBOV subspecies were stably introduced into 293 T-REx cells,
which express transgenes upon induction with tetracycline. The
293 T-REx cell line, a derivative of the 293 cell line, was chosen
because these cells are readily transfectable and should allow
efficient production of reporter viruses bearing EBOV-GPs.
Western blot analysis of 293 T-REx cell lines stably transfected
with EBOV-GP expression constructs revealed that all cell lines
expressed the EBOV-GPs in a doxycycline (a tetracycline
derivative)-dependent fashion, while no GP signal was detected
in parental 293 control cells (Fig. 1A). The rabbit serum used
for detection of EBOV-GP expression was raised against
ZEBOV-GP and preferentially recognizes this protein (data not
shown); therefore, differences in the signal intensities between
Fig. 1. Inducible expression of EBOV-GP and incorporation of different amounts of EBOV-GP into reporter viruses. (A) Inducible expression of EBOV-GP in 293 T-
REx cells. The 293 cell derived cell line 293 T-REx, which encodes a tetracycline (tet)-sensitive repressor, was transiently transfected with expression constructs
encoding the GPs of the four EBOV subspecies under control of a CMV promoter harboring two binding sites for the tet-repressor. After prolonged culture in the
presence of selection antibiotics resistant cell populations were obtained and expanded. Expression of GP in the indicated stable cell lines was induced with the
indicated amounts of doxycycline (a tetracycline derivative) and GP expression in cell lysates was analyzed by Western blot, employing a ZEBOV-GP-specific serum
for detection. Similar results were obtained in two independent experiments. Asterisks mark GP detected upon induction with 100 ng/ml doxycycline. Abbreviations:
Dox, doxycycline. ZEBOV, Zaire ebolavirus; SEBOV, Sudan ebolavirus; ICEBOV, Ivory Coast ebolavirus; REBOV, Reston ebolavirus; GP, glycoprotein. (B)
Inducible expression of ZEBOV-GP on the surface of 293 T-REx cells. ZEBOV-GP expression in 293 T-REx cells was induced with the indicated amounts of
doxycycline and analyzed by FACS employing a ZEBOV-GP-specific serum for detection. The results were confirmed in two independent experiments. The black
filled histogram indicates staining of parental 293 T-REx cells with the ZEBOV-GP-specific serum. (C) Expression of ZEBOV-GP upon induction with doxycycline
was assessed as described for (B) and geometric mean channel fluorescence was determined. The average of three independent experiments is shown, error bars
indicate standard error of the mean (SEM). (D) Incorporation of differential amounts of EBOV-GP into lentiviral reporter viruses. The EBOV-GP transfected 293 T-
REx cell lines were induced to express GP, transfected with the env-defective HIV-1 pNL4-3-Luc-R−E− reporter virus genome, and culture supernatants harvested
thereafter. Equal volumes of viral supernatants containing 2.5 ng of viral capsid antigen were pelleted and the presence of GP and capsid in viral pellets analyzed by
Western blot. Similar results were obtained upon analysis of two independently generated virus stocks. Bands corresponding to GP are marked by asterisks.
Densitometric analysis of ZEBOV- and REBOV-GP signals of three independent Western blot experiments yielded the following results (calculated relative to the
ZEBOV-GP signal measured upon GP induction with 100 ng/ml doxycycline, which was set as 100%): 94.5 ± 15 for REBOV-GP at 100 ng/ml doxycycline; 6.9 ± 4.2
for ZEBOV-GP at 1 ng/ml doxycycline and 0.7 ± 0.4% for REBOV-GP at 0 ng/ml doxycycline. The signals measured for REBOV-GP at 1 ng/ml and for ZEBOV-GP
at 0 ng/ml doxycycline were below background.
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expression but are most likely due to differential reaction with
the antiserum employed for detection. The relative gel mobility
of the GPs analyzed is in agreement with documented results
(Feldmann et al., 1994; Marzi et al., 2006). Several bands were
observed in control and GP expressing cells (particularly in the
range of 40 to 70 kDa) and most likely reflect unspecific
reactivity of the rabbit serum; albeit it cannot be excluded that
some signals originate from, or are enhanced by, products of GP
degradation.
We next analyzed surface expression of GPs on doxycycline
induced 293 T-REx cells. Relatively weak signals were
observed for SEBOV- and ICEBOV-GP, while REBOV- and
particularly ZEBOV-GP expression was readily detectable (Fig.
1B and data not shown), which is generally in agreement withthe results obtained upon Western blot analysis of GP
expression (Fig. 1A). Analysis of ZEBOV- and REBOV-GP
producing cells revealed doxycycline-dependent GP expression
(Figs. 1B, C and data not shown), albeit the correlation between
inducer concentration and GP expression was not as strict as
observed upon Western blot analysis (Fig. 1A). Notably, some
ZEBOV-GP was expressed also on uninduced cells, suggesting
that the negative regulation of GP expression in the absence of
inductor was not entirely tight.
Having demonstrated inducible expression of GP on 293 T-
REx cells, we then sought to use these cells to produce reporter
viruses pseudotyped with different amounts of GP. Previous
studies found that pseudotypes bearing the EBOV-GP are an
adequate model to study EBOV-GP-dependent cellular entry
under standard biosafety conditions (Takada et al., 1997; Wool-
348 A. Marzi et al. / Virology 352 (2006) 345–356Lewis and Bates, 1998; Yang et al., 1998). To this end, a
proviral HIV-1 reporter genome was transiently expressed in
293 T-REx cells lines and the cells induced to produce high and
low levels of GP. Western blot analysis of pelleted viral
supernatants revealed that viruses produced in the presence of
100 ng/ml doxycycline had indeed incorporated readily
detectable amounts of GP (Fig. 1D). In contrast, little or no
GP was detected in pelleted supernatants when GP expression
was induced with 100-fold less doxycycline or no doxycycline
(Fig. 1D). Thus, stable introduction of EBOV-GP expression
constructs into 293 T-REx allowed controlled expression of GP,
which in turn enabled us to generate reporter viruses harboring
different amounts of GP.
Differential induction of cell rounding upon expression of the
GPs of the four EBOV subspecies
Expression of EBOV-GP alters cellular functions, a property
that might contribute to EBOV pathogenesis. One consequence
of GP expression is cell rounding and subsequent detachment
from culture plates (Chan et al., 2000; Simmons et al., 2002;
Takada et al., 2000; Yang et al., 2000). It has previously been
reported that expression of ZEBOV- and SEBOV-GP triggers
cell rounding with high efficiency, while this effect was less
pronounced upon expression of REBOV-GP (Simmons et al.,
2002). We investigated if induced expression of the GPs of the
four EBOV subspecies triggered detachment of 293 T-REx cells
from culture plates. In agreement with previous results
(Simmons et al., 2002), we found that doxycycline induced
expression of ZEBOV- and SEBOV-GP caused substantial cell
detachment in a dose-dependent fashion (Fig. 2). In contrast,
floating cells were only detected upon maximal induction of
REBOV-GP expression, and no appreciable cell detachment
was observed upon expression of ICEBOV-GP (Fig. 2). Thus,Fig. 2. The GPs of the four EBOV subspecies induce detachment of 293 T-REx
cells from culture plates with differential efficiencies. EBOV-GP expression by
293 T-REx cells was induced with the indicated concentrations of doxycycline
and the number of cells floating in the culture supernatants 48 h after induction
was determined by FACS. Results represent the average of three independent
experiments, error bars indicate SEM. In a representative experiment performed
in quadruplicates, induction with 100 ng/ml doxycycline resulted in detachment
of 696 ± 169 control cells, 13284 ± 5080 ZEBOV-GP T-REx cells,
20545 ± 7036 SEBOV-GP T-REx cells, 5320 ± 866 REBOV-GP T-REx cells
and 2169 ± 761 ICEBOV-GP T-REx cells.our observations generally confirm previous reports (Chan et al.,
2000; Simmons et al., 2002; Takada et al., 2000; Yang et al.,
2000) and indicate that the GPs expressed upon induction in 293
T-REx cell lines exhibit comparable cytopathic properties as
GPs conventionally expressed upon transient transfection.
Relatively low levels of virion incorporation suffice for efficient
EBOV-GP-driven infection
The level of virion incorporation of GP can determine the
efficiency of HIV-1 and SIV entry into susceptible cells
(Bachrach et al., 2005; Yuste et al., 2004, 2005). We employed
reporter viruses harboring different amounts of EBOV-GP to
assess if the efficiency of EBOV-GP-driven entry also depends
on the amount of GP present in the viral envelope. Reporter
viruses encoding the luciferase gene and bearing different levels
of EBOV-GP were produced as described above. As a control,
reporter viruses bearing vesicular stomatitis virus glycoprotein
(VSV-G) were produced upon cotransfection of constant
amounts of plasmids encoding VSV-G and the reporter virus
genome (both expressed constitutively) into parental 293 T-REx
cells, which were subsequently incubated with the indicated
doxycycline concentrations (Fig. 3). All virus stocks were
normalized for equal content of p24-capsid antigen and used for
infection of 293T and Huh-7 cells, which are both susceptible to
EBOV-GP and VSV-G-driven infection. Cells infected with
these reporter viruses express luciferase under control of the
viral promoter and only upon successful integration of the
proviral genome into the cellular genome. Therefore, luciferase
activities in lysates of reporter virus inoculated cells are an
adequate parameter for infection efficiency. All EBOV-GP
bearing viruses generated in the absence of doxycycline and
thus in the absence of appreciable GP expression were
noninfectious (Fig. 3). Thus, the low levels of GP present on
uninduced ZEBOV-GP 293 T-REx cells (Fig. 1B) and possibly
the other GP transfected cells were not sufficient to support
infectious cellular entry of viruses produced in these cells,
because either no GP or insufficient GP copies were
incorporated into budding virions. In contrast, reporter viruses
produced by cells in which GP expression was induced by 1 and
100 ng/ml doxycycline were highly infectious for both 293T
and Huh-7 cells (Fig. 3). In the case of ZEBOV- and SEBOV-
GP, no substantial difference in infectivity was observed
between viruses produced by cells induced with 1 or 100 ng/
ml doxycycline. In contrast, ICEBOV-GP and particularly
REBOV-GP bearing viruses were reproducibly up to 10-fold
more infectious when GP expression in virus producing cells
was induced by 100 instead of 1 ng/ml doxycycline (Fig. 3).
This doxycycline-dependent increase in GP expression, virion
incorporation (Fig. 1) and infectivity suggests that a relatively
high number of virion associated REBOV- and ICEBOV-GP
copies might be necessary for full infectivity. However, the
infectivity of reporter viruses bearing VSV-G also increased
slightly upon addition of rising amounts of doxycycline to virus
producing cells (Fig. 3). Thus, albeit EBOV-GP and VSV-G
bearing viruses were generated under differential conditions
(EBOV-GP expression was induced by doxycycline while VSV-
Fig. 3. Impact of the efficiency of GP incorporation into virions on viral infectivity. Reporter viruses bearing different amounts of the GPs of the four EBOV subspecies
were produced as described in the legend to Fig. 1. VSV-G harboring control viruses were generated upon cotransfection of parental 293 T-REx cells with plasmids
encoding VSV-G and the reporter virus genome (both designed for constitutive expression). Equal volumes of viral supernatants containing 0.1 ng of p24-capsid
antigen were added to 293T and Huh-7 cells and the luciferase activities in cellular lysates determined 3 days after infection. The results of a representative experiment
performed in triplicates are shown, error bars indicate standard deviation (SD). Comparable results were obtained in two separate experiments performed with
independent virus stocks.
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not be directly compared, these results indicate that the
increased infectivity of viruses bearing high amounts of
REBOV- and ICEBOV-GP could at least in part be due to
unspecific effects. We finally analyzed if induction of GP
expression by doxycycline concentrations of less than 1 ng/ml
resulted in reporter viruses with intermediate infectivity, but
found that viruses produced under these conditions were barely
or non infectious (data not shown). In summary, we conclude
that a substantial range of virion associated GP copy numbers
allows for constant and robust infectivity of EBOV-GP bearing
pseudotypes.
Optimal usage of cellular lectins for augmentation of infectivity
requires high levels of EBOV-GP incorporation into virions
Several cellular lectins recognize carbohydrates in EBOV-
GP and augment infectious viral entry into already permissive
cells (Alvarez et al., 2002; Becker et al., 1995; Gramberg et al.,
2005; Lin et al., 2003; Simmons et al., 2003; Takada et al.,
2004). In some cases, EBOV-GP engagement of lectins might
even be sufficient to allow infection of otherwise nonpermissive
cells (Alvarez et al., 2002), albeit this concept is currently under
debate. In any event, filovirus binding to cellular lectins might
promote viral spread in infected patients and the parameters
controlling this interaction merit investigation. We asked if the
efficiency of EBOV-GP interactions with lectins depends on the
level of GP incorporation into virions. In order to address this
question, we infected permissive 293 T-REx cells expressing
lectins known to augment filovirus infection with reporter
viruses bearing different amounts of EBOV-GP. VSV-G bearing
viruses were produced as described above and employed as
controls. All input viruses were normalized for comparable
infection of parental 293 T-REx cells, thereby allowing direct
comparison of lectin mediated augmentation of infection. As
expected from previous reports (Alvarez et al., 2002; Becker et
al., 1995; Lin et al., 2003; Simmons et al., 2003; Takada et al.,
2004), all lectins examined enhanced infection driven by theGPs of the four EBOV subspecies, albeit with differential
efficiency, while lectin expression did not appreciably modulate
VSV-G-dependent infection (Fig. 4). Lectin engagement by
ZEBOV- and REBOV-GP bearing reporter viruses was
moderately but consistently enhanced upon incorporation of
high amounts of GP into virions (Fig. 4), suggesting that the
number of ZEBOV- and REBOV-GP trimers incorporated in the
viral envelope can limit the interaction with lectins. In contrast,
a less pronounced effect was observed with SEBOV-GP bearing
viruses and virion incorporation of ICEBOV-GP, which
generally interacted with lectins with low efficiency, did not
seem to modulate lectin usage (Fig. 4), suggesting that other
constrains might limit the lectin engagement of these GPs.
Thus, in some cases, the number of EBOV-GP copies in the
viral envelope can modulate virus capture by cellular lectins and
might impact viral spread in lectin expressing cells.
Virion incorporation of high amounts of GP increases
neutralization sensitivity
The filovirus GP is the major target for neutralizing
antibodies. For SIV it has been observed that the number of
GP copies incorporated into the viral envelope can modulate the
efficiency of antibody mediated neutralization (Yuste et al.,
2005). We compared neutralization of reporter viruses bearing
low and high amounts of ZEBOV-GP by a rabbit serum raised
against ZEBOV-GP. VSV-G bearing viruses produced in the
presence of doxycycline were used as controls, and all viruses
were normalized for comparable infection of 293 T-REx cells in
the absence of antiserum. As expected, VSV-G-driven infection
could not be blocked by the antiserum (Fig. 5), and several
control sera had no appreciable effect on ZEBOV-GP-
dependent infection (data not shown). In contrast, incubation
of ZEBOV-GP bearing viruses with antiserum before their
addition to target cells diminished infection efficiency, albeit
with moderate efficiency. Notably, at a serum dilution of 1:25,
but not at higher dilutions, the infection by viruses bearing
relatively high amounts of ZEBOV-GP was more efficiently
Fig. 4. Virion incorporation of high amounts of ZEBOV- and REBOV-GP is required for optimal engagement of attachment factors. Reporter viruses bearing different
amounts of the GPs of the four EBOV subspecies were produced as described in the legend to Fig. 1. VSV-G harboring control viruses were generated upon
cotransfection of parental 293 T-REx cells with plasmids encoding VSV-G and the reporter virus genome. Viruses were normalized for comparable infection of
parental 293 T-REx cells and employed to infect 293 T-REx cell lines expressing the indicated lectins. Luciferase activities in cellular lysates were determined three
days after inoculation, and values obtained upon infection of parental 293 T-REx cells were set as 100%. The results represent the average of two to five independent
experiments carried out in triplicates. Error bars indicate SEM.
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amounts of ZEBOV-GP (Fig. 5, 66% reduction compared to
36% reduction, average of three experiments with independent
virus stocks), suggesting that the GP density in the viral
envelope might impact EBOV susceptibility to neutralizing
antibodies.
Expression of ZEBOV-GP in target cells does not interfere with
ZEBOV-GP-dependent entry but blocks VSV-G-driven infection
in a dose-dependent manner
The expression of viral GPs can interfere with surface
expression of the respective viral receptors. For example, the
HIV-1 Env traps the CD4 receptor in the endoplasmaticFig. 5. Increasing the amount of GP on the virion surface increase neutralization
sensitivity. Reporter viruses bearing different amounts of ZEBOV-GP were
produced as described in the legend to Fig. 1. VSV-G harboring control viruses
were generated upon cotransfection of parental 293 T-REx cells (induced with
100 ng/ml doxycycline) with plasmids encoding VSV-G and the reporter virus
genome. Viruses were normalized for comparable infection of 293T cells. Equal
volumes of virus stocks of comparable infectivity were incubated with ZEBOV-
GP-specific rabbit serum for 30 min at 37 °C and subsequently added to 293T
cells. Luciferase activities in cellular lysates were measured 3 days after
infection. The average of three separate experiments performed in triplicates
with independent virus stocks are shown. Error bars indicate SEM.reticulum, thereby leading to reduced expression of CD4 on
the cell surface (Hoxie et al., 1986; Martin and Nayak, 1996a,
1996b). Therefore, induction of EBOV-GP expression in
permissive 293 T-REx cells might downmodulate the so far
unidentified EBOV receptor(s) and might reduce EBOV-GP-
driven entry. We investigated this possibility by infecting
ZEBOV-GP expressing and control 293 T-REx cells with
pseudotypes bearing ZEBOV-GP, VSV-G or the GP of
amphotropic murine leukemia virus (A-MLV). Treatment of
control 293 T-REx cells with different doses of doxycycline had
no appreciable impact on infection by all pseudotyped viruses
tested (Fig. 6, left panel). Similarly, doxycycline mediated
induction of ZEBOV-GP expression in 293 T-REx cells did not
alter susceptibility to ZEBOV-GP-dependent infection (Fig. 6,
right panel). However, expression of ZEBOV-GP reduced VSV-
G and A-MLV-GP-driven entry in a dose-dependent fashion
(Fig. 6, right panel), suggesting that ZEBOV-GP productionFig. 6. Expression of ZEBOV-GP blocks VSV-G and A-MLV-GP but not
ZEBOV-GP-driven entry. Parental 293 T-REx cells (left panel) and ZEBOV-GP
transfected 293 T-REx cells (right panel) were induced with the indicated
amounts of doxycycline and the cells inoculated with reporter viruses bearing
VSV-G, A-MLV-GP or ZEBOV-GP. Luciferase activities in cellular lysates were
determined 3 days after infection. The average of three independent experiments
is presented, error bars indicate SEM.
351A. Marzi et al. / Virology 352 (2006) 345–356might interfere with cellular factors required for VSV-G and A-
MLV-GP-dependent infection.
Discussion
EBOV-GP mediates the first indispensable step in the viral
life cycle, virus entry into cells, and is the major target of
neutralizing antibodies. However, it is unclear if the level of
EBOV-GP incorporation into virions impacts the interaction
with cellular factors and the susceptibility to neutralizing
antibodies. By employing reporter viruses bearing low and high
amounts of EBOV-GP, we provide evidence that increased GP
incorporation into virions can augment engagement of cellular
attachment factors and increases neutralization by antibodies.
Moreover, we show that EBOV-GP expression does not reduce
susceptibility to EBOV-GP-dependent infection, suggesting
that GP does not interfere with expression of its cognate cellular
receptor(s). However, EBOV-GP expression diminished VSV-
G and A-MLV-GP-driven infectious entry and might therefore
modulate cellular functions exploited by VSV, A-MLV and
possibly other viruses for infectious entry.
We employed a doxycycline inducible system in order to
achieve regulated production of EBOV-GP. Upon transfection
and subsequent selection with antibiotics, 293 cell lines were
obtained that express the GPs of the four EBOV subspecies in a
doxycycline-dependent manner (Figs. 1A–C). Comparable
induction of GP expression upon doxycycline induction was
observed over several passages, and the cells could be
employed to generate reporter viruses bearing different amounts
of GP (Fig. 1D). Thus, the generated cell lines constitute
valuable tools to assess GP function. Despite the clear induction
of GP expression upon addition of doxycycline to cell lines, we
only managed to induce relatively low and relatively high
amounts of GP but failed to consistently induce a range of
intermediate levels of expression. This limitation might be in
part inherent to the particular inducible expression system used,
which was mainly designed to guarantee either complete shut
down or full expression of the gene of interest. More recently
generated tetracycline inducible systems allow efficient induc-
tion of intermediate expression of the gene under study (Berens
and Hillen, 2004) and might be more suitable for fine regulation
of GP expression. Finally, we note that reduction of doxycycline
from 100 to 1 ng/ml resulted in clearly diminished GP
expression as judged by Western blot, while FACS analysis
revealed only a moderated decrease of GP expression on the cell
surface (compare Figs. 1A and B, C). Once a certain level of GP
expression is reached, the protein might thus accumulate
preferentially in intracellular compartments and to a lesser
degree at the cell surface. Remarkably, the efficiency of GP
incorporation into lentiviral particles seemed to correlate
roughly with the amount of GP present in cell lysates and not
with surface expressed GP, albeit we cannot exclude that the
apparent reduction of virion incorporation of GP was partly
exacerbated by a nonlinear decrease of reactivity of the
antiserum upon analysis of very low amounts of GP. In any
event, these observations raise the possibility that a substantial
fraction of virion incorporation of GP occurred intracellularly.In fact, Sandrin and colleagues observed that incorporation of
certain heterologous GPs into retro- and lentiviral particles can
occur in late endosomes (Sandrin et al., 2004; Sandrin and
Cosset, 2006).
Expression of ZEBOV- and SEBOV-GP was previously
shown to cause cell rounding and detachment of cells from
culture plates, while the effects of REBOV-GP on cellular
attachment to culture plates were less profound (Simmons et al.,
2002). These observations were made with cell lines transiently
expressing GP or cells infected with adenovirus encoding GP.
Similarly, in 293 T-REx cells, which express GP upon induction
with doxycycline, profound cellular detachment was observed
upon induction of ZEBOV- and SEBOV-GP expression,
whereas REBOV-GP and ICEBOV-GP were less active in this
system (Fig. 2). It should be noted, however, that in the T-REx
cell system, SEBOV-GP was more active compared to ZEBOV-
GP, at least under conditions of maximum induction of GP
expression, while the reverse finding was made with transiently
transfected cells (Simmons et al., 2002). Differences in GP
expression levels might account for this discrepancy. Thus, GP
produced in 293 T-REx cells generally resembled GP generated
in widely used transient systems in its ability to diminish
cellular attachment to culture plates, indicating that during
selection of stable cells no GP variants with reduced
interference with cellular adhesion functions were selected.
Cellular entry of enveloped viruses is brought about by a
series of complex interactions of the viral envelope GP with
cellular factors (Dimitrov, 2004; Smith and Helenius, 2004). GP
engagement of cellular receptors activates GP-driven fusion of
the viral and a cellular membrane, which ultimately results in
the introduction of the viral genome into the cellular cytoplasm.
Albeit several candidate molecules have been proposed (Chan
et al., 2001; Takada et al., 2000), the cellular receptor for EBOV
remains elusive and the processes activating GP-driven
membrane fusion are therefore incompletely understood. Our
results indicate that a range of GP copies presented on the
surface of virions is sufficient to allow entry into cells with
comparably high efficiency (Fig. 3). Therefore, even EBOV
particles bearing relatively few copies of GP might be highly
infectious, which would have implications for strategies aiming
at the inhibition of GP function (as discussed below).
In contrast to GP interactions with receptors, which are
essential for infectious entry into cells, GP binding to so-called
attachment factors can strongly augment infection efficiency
but is ultimately dispensable for entry (Baribaud et al., 2002).
Binding of filovirus GPs to certain cellular lectins has been
shown to augment infectious entry into already permissive cells
(Alvarez et al., 2002; Becker et al., 1995; Lin et al., 2003;
Simmons et al., 2003; Takada et al., 2004). Lectin mediated
enhancement of EBOV infectivity might be due to concentra-
tion of virions on the cell surface and therefore increased entry
via so far unidentified cellular receptors, albeit in some
instances lectins might serve as true viral receptors (Alvarez
et al., 2002). It has been shown that the number of lectin copies
expressed on target cells and the presence, and most likely
adequate spatial distribution, of appropriate carbohydrates on
the EBOV-GP surface can determine the interaction with lectins
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evidence that also the number of EBOV-GP copies inserted into
the viral envelope can impact lectin engagement, with viruses
bearing a higher number of GP molecules being more adept in
engagement of lectins (Fig. 4), a result we confirmed for
ZEBOV-GP in a transient system, as part of a separate study
(Marzi et al., 2006). This correlation was particularly evident for
viruses bearing ZEBOV- and REBOV-GP, while the level of
ICEBOV-GP virion incorporation did not seem to alter
interactions with cellular lectins (Fig. 4). Lectin binding of
ICEBOV-GP bearing viruses was generally weak. Since these
viruses attached robustly to control cells (data not shown)
determinants in ICEBOV-GP might specifically prevent the
engagement of certain lectins. Indeed, forced incorporation of
high mannose carbohydrates into ICEBOV-GP allowed effi-
cient interactions with the mannose, fucose-specific lectin DC-
SIGN (data not shown), indicating that the carbohydrate
modifications of ICEBOV-GP could limit lectin engagement.
In summary, these observations suggest that binding of multiple
GP trimers to cellular lectins might in some instances be
required for optimal augmentation of EBOV infection by
lectins.
Recently described vaccines that provide efficient protection
against filovirus infection induce cellular as well as humoral
immune responses (Jones et al., 2005; Warfield et al., 2005),
and both might be required to control infection. In one study, the
vaccine induced humoral immune response was clearly more
prominent than the cellular response but did not efficiently
neutralize the virus in in vitro systems (Jones et al., 2005).
Therefore, it was suggested that a vigorous albeit nonneutraliz-
ing antibody response might be sufficient to provide protection
against filovirus infection (Jones et al., 2005). Nevertheless,
production of neutralizing antibodies upon vaccination is
obviously desirable, and the parameters determining neutrali-
zation efficiency are of interest. We observed that the amount of
GP incorporation into virions affects neutralization sensitivity,
with virions bearing more GP being more susceptible to
neutralization, at least when neutralization by a low dilution of
antiserum was assessed (Fig. 5). Notably, the inverse correlation
has been documented for a SIV variant, for which infectivity
and resistance to neutralization increased with the amount of
virion associated Env protein (Yuste et al., 2005). The latter
observation can be explained in a straight forward fashion with
more Env trimers on the virion surface requiring a higher
amount of antibodies for their inactivation (Yuste et al., 2005).
However, it cannot be excluded that antibodies must recognize
most or all SIV Env copies on the virion surface in order to
inhibit infection, while antibody binding of a few copies of
virion associated EBOV-GP might be sufficient to block entry.
In this case, particles harboring low amounts of GP would be
less efficiently recognized by serum and therefore more
resistant to neutralization, despite displaying equal infectivity
as particles bearing high amounts of GP (Fig. 3).
Retroviruses (Levesque et al., 2004; Ruibal-Ares et al.,
2004) and several other viruses (Breiner et al., 2001; Horga et
al., 2000; Kuba et al., 2005; Naniche et al., 1993; Schneider-
Schaulies et al., 1995; Yamate et al., 2005) have evolvedstrategies to negatively regulate the surface expression of their
receptors on infected cells, most likely to avoid superinfection
and to ensure that progeny particles detach efficiently from
infected cells. One mechanism that causes downregulation of
the HIV-1 receptor CD4 from the cell surface is Env mediated
trapping of CD4 in the endoplasmatic reticulum (Hoxie et al.,
1986; Martin and Nayak, 1996a, 1996b). Expression of EBOV-
GP leads to downmodulation of many surface molecules
(Simmons et al., 2002), including β1-integrins and α5β3
integrin (Sullivan et al., 2005; Takada et al., 2000), and
members of the former group of integrins have been proposed to
function as EBOV receptors (Takada et al., 2000). In our hands
induced expression of ZEBOV-GP in 293 T-REx cells did not
interfere with ZEBOV-GP-driven infection (Fig. 6), suggesting
that in this cellular system GP does not appreciably modulate
expression of its receptor. However, ZEBOV-GP expression
caused a profound and dose-dependent reduction of VSV-G and
A-MLV-GP-driven infection, suggesting that ZEBOV-GP
interferes with the expression and/or function of cellular factors
required for VSV-G and A-MLV-GP-dependent entry. It has
been suggested that phosphatidylserine, an ubiquitous mem-
brane lipid present mainly in the inner leaflet of the plasma
membrane, is an entry receptor for VSV (Hall et al., 1998;
Schlegel et al., 1983; Schlegel and Wade, 1983). Albeit a
function of phosphatidylserine as VSV receptor has been
challenged (Coil and Miller, 2004; Coil and Miller, 2005), an
important role of this lipid in VSVentry, possibly after receptor
engagement, is likely, and it can be speculated that EBOV-GP
might alter the phosphatidylserine content of cellular mem-
branes. Similarly, EBOV-GP might modulate surface expres-
sion of the multimembrane-spanning phosphate transporter
Pit2, the entry receptor for A-MLV (Kavanaugh et al., 1994;
Miller et al., 1994; van Zeijl et al., 1994). Another potential
explanation for the interference of ZEBOV-GP expression with
VSV-G and possibly also A-MLV-GP-driven entry is the
recently documented GP interaction with the GTPase dynamin,
which is involved in the release of vesicles from lipid rafts into
the cellular cytoplasm (Conner and Schmid, 2003). Since VSV-
G mediated infection involves virion endocytosis in a probably
dynamin-dependent fashion (Daecke et al., 2005; Lee et al.,
1999) and subsequent fusion with endosomal membranes, it is
conceivable that GP interference with dynamin function might
inhibit VSV-G-dependent cellular entry. A-MLV is believed to
fuse with the plasma membrane (McClure et al., 1990), but
endocytic entry of A-MLV has recently been documented (Beer
et al., 2005) and dynamin might be involved in this process.
However, dynamin is required for both, entry via clathrin coated
pits, the route employed by VSV (Superti et al., 1987), and for
cellular uptake of viruses via caveolae, the route used by EBOV-
GP bearing pseudotypes (Empig and Goldsmith, 2002) and A-
MLV, at least for uptake into NIH 3T3 cells (Beer et al., 2005).
Therefore, one would need to argue that EBOV-GP selectively
interferes with dynamin functions required for VSV-G and A-
MLV-GP but not EBOV-GP-dependent entry.
In summary, our data provide evidence that the number of
EBOV-GP copies incorporated into virions might affect
engagement of cellular lectins and susceptibility to antibody
353A. Marzi et al. / Virology 352 (2006) 345–356mediated neutralization. Moreover, our results suggest that a
relatively broad range of virion associated GP copies might
mediate highly efficient cellular entry of virions. In the light of
these observations, it would be interesting to investigate if the
GP content of filoviruses depends on, e.g., the viral isolate, the
producer cell type or the stage of infection and if differences in
the amount of virion associated GP have functional conse-
quences. These undertakings require access to P4 facilities and
are beyond the scope of the present study.
Material and methods
Plasmid construction, cell culture and generation of stable
EBOV-GP expressing cell lines
The ORFs of the four different Ebolavirus glycoproteins
(EBOV-GPs) were generated by insertion of these genes in
pcDNA4/TO (Invitrogen, CA, USA) via HindIII and XbaI as
described (Gramberg et al., 2005). 293 T-REx cells were
maintained in Dulbecco's modified Eagle's medium (DMEM,
Gibco/BRL, Eggenstein, Germany) supplemented with 10%
FCS, penicillin, streptomycin and 2.5 μg/ml blasticidin
(Invitrogen, CA, USA). 293 T-REx cell lines stably expressing
EBOV-GPs were generated by transfection with the indicated
expression plasmids followed by selection for 2 weeks in
DMEM containing 10% FCS, penicillin, streptomycin, 2.5 μg/
ml blasticidin and 50 μg/ml zeocin (Invitrogen, CA, USA).
Lectin expressing T-REx cell lines were also maintained in
DMEM supplemented with FCS, penicillin, streptomycin,
blasticidin and zeocin as described previously (Simmons et
al., 2003). EBOV-GP and lectin expression on T-REx cells was
induced with doxycycline (Sigma, Deisenhofen, Germany) at
final concentrations of 0.1, 0.5, 1 or 100 ng/ml. 293T and Huh-7
cells were propagated in DMEM supplemented with 10% FCS,
penicillin and streptomycin.
Western blot and FACS analysis
Western blot analysis was performed with equal amounts
of 293 T-REx cells induced to express different levels of
EBOV-GP for 24 h or with concentrated viral supernatants
containing 2.5 ng capsid protein (p24) antigen as determined
by enzyme-linked immunosorbent assay (ELISA; Murex;
Abbott Diagnostics, IL, USA). Viruses were pelleted by
centrifugation for 2 h at 14,000 rpm at 4 °C, lysed in SDS
Laemmli buffer and boiled at 95 °C for 15 min. Cells were
harvested, also lysed in SDS Laemmli buffer and boiled at
95 °C for 15 min. Proteins were then separated by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE, employing 10% PAA gels), transferred onto nitrocel-
lulose membranes (Schleicher and Schuell, Dassel, Germany)
and blocked o/n at 4 °C in 5% skim milk in PBS
supplemented with 0.1% Tween. EBOV-GP and HIV-1 p24-
antigen were detected with polyclonal rabbit sera used at a
dilution of 1:1000 (the EBOV-GP-specific serum was raised
against ZEBOV-GP) and appropriate secondary antibody
coupled to peroxidase. Chemoluminescence detection wasperformed according to the manufacturer's protocol (Amer-
sham Pharmacia Biotech Europe, Freiburg, Germany).
For FACS analysis of GP expression the indicated EBOV-GP
293 T-REx cell lines were induced to express different levels of
GP over a period of 24 h, harvested and incubated with the
polyclonal anti GP rabbit serum at a 1:150 dilution in a total
volume of 100 μl FACS buffer (PBS with 3% FCS; 0.01%
NaN3) for 30 min at 4 °C. After a washing step, the bound
antibody was detected by incubating the cells in 100 μl FACS
buffer containing 0.5 μg of anti-rabbit-FITC (Dianova, Ham-
burg, Germany). Antibody binding was allowed to proceed for
30 min at 4 °C, then cells were washed, and EBOV-GP surface
expression was quantitated by FACS analysis employing a
FACSCalibur flow cytometer (Becton Dickinson, NJ, USA).
Assessment of EBOV-GP induced detachment of cells from
culture flasks
2 × 105 cells per well of EBOV-GP transfected 293 T-REx
cells were seeded into 12-well plates, GP expression was
induced by different concentrations of doxycycline, and after
48 h, the supernatants were collected. Floating cells in the
supernatants were pelleted by centrifugation, washed for two
times in FACS buffer and counted by FACS analysis using a
FACSCalibur flow cytometer (Becton Dickinson, NJ, USA).
Production of pseudotyped reporter viruses, infection assays
and inhibition with ZEBOV-GP-specific antiserum
Pseudotypes harboring different amounts of EBOV-GP were
generated by transfection of pNL4-3-Luc-R-E- (Connor et al.,
1995) into EBOV-GP 293 T-REx cell lines, which were induced
to express GP 1 h before transfection. Pseudotypes bearing
constant, high amounts of GP were generated by cotransfection
of 293T cells with pNL4-3-Luc-R−E− and ZEBOV-, A-MLV-
GP or VSV-G expression plasmids. 48 h after transfection the
culture supernatants were harvested, passed through 0.4 μm-
pore-size filters, aliquoted and stored at −80 °C. For subsequent
infection experiments, the supernatants were either normalized
for comparable content of HIV-1 p24-antigen employing
antigen capture ELISA (Murex; Abbott Diagnostics, IL, USA)
or normalized for comparable infection of control cells, which
was determined by assessing luciferase activities in the lysates
of infected cells employing a commercially available kit as
recommended by the manufacturer (Promega, WI, USA).
Infections were carried out by seeding the indicated cell lines
onto 96-well plates at a density of 1 × 104 per well followed by
addition of virus normalized either for infectivity or p24-antigen
content in a total volume of 100 μl per well. For serum
inhibition experiments, viruses were preincubated with a
polyclonal rabbit serum raised against ZEBOV-GP at the
indicated dilutions for 30 min prior to infection. For analysis of
interference of ZEBOV-GP expression with permissiveness to
VSV-G, A-MLV-GP or ZEBOV-GP-driven infection, GP
expression was induced in target cells 12 h prior to infection.
For assessment of lectin mediated augmentation of EBOV-GP-
dependent infection, lectin expression was induced on T-REx
354 A. Marzi et al. / Virology 352 (2006) 345–356target cells with 100 ng/ml doxycycline 12 h before addition of
viral supernatants. Cells were incubated with virus for 12 h, and
thereafter, medium was replaced and luciferase activities were
determined 72 h after infection with a commercially available
kit (Promega, WI, USA).
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